AGN Patent Application News Summary Algernon Pharmaceuticals (AGN.c AGNPF) closed in the green today after announcing it received a Notice of Allowance from the US Patent and Trademark Office for its patent application for its lead chronic kidney disease (CKD) drug Repirinast.
Repirinast has shown promising results in reducing hepatic fibrosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH).
Repirinast is also being investigated as a treatment for CKD, as patients with NAFLD have an increased risk of developing CKD.
Repirinast works by binding to receptors on mast cells to prevent their degranulation, which AGN believes could help prevent fibrosis in multiple organs, including the kidneys and the liver.
More here:
https://www.globenewswire.com/news-release/2023/04/17/2647769/0/en/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Method-of-Use-U-S-Patent-Application.html